abbv-467
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2019 (NCT04178902)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(Cl)c2c(Cl)c(C)c1-c1c(-c3ccc(F)cc3)sc3ncnc(c13)O[C@@H](C(=O)O)Cc1cc(ccc1OCc1ccnc(-c3ccc(OC[C@H]4COCCO4)cc3)n1)OC[C@@H](CN1CCN(C)CC1)O2- Mol. weight
- 1037.99 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6033457 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06878248 | Phase 1 | Apr 17, 2025 | Calibr-Skaggs Institute for Innovative Medicines, California Institute for Biomedical Research |
| NCT04178902 | Phase 1 | Nov 26, 2019 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2019 |
| Calibr-Skaggs Institute for Innovative Medicines | Academic/Hospital | 1 | 0 | 1 | 2025 |
| California Institute for Biomedical Research | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1